Clinical trial
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of QLS1128 Orally in Symptomatic Participants With Mild to Moderate COVID-19
NCT05689203 is registered in ClinicalTrials.gov with Qilu Pharmaceutical Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of QLS1128 Orally in Symptomatic Participants With Mild to Moderate COVID-19
- Lead sponsor
- Qilu Pharmaceutical Co., Ltd.
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- December 30, 2022
- Completion date
- February 1, 2023
- Enrollment
- 360 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.